Global Isotretinoin Drugs Market, By Form

Growth Outlook

• The Global Isotretinoin Drugs Market, By Form market is on a steady long-term growth path. Segment value stands at roughly USD 1561 Mn in 2026 and is projected to reach USD 1652 Mn by 2027 — a gain of about 6% over the forecast period, translating to a CAGR in the mid-single digits.
• By 2027, Capsule is the largest of the 2 groups tracked here, at 1. 17B USD, 71% of the combined total.
• What the regional split looks like (2026): Capsule leads, holding roughly 71% of segment value — the single largest regional share. Injection is the second-largest contributor.
• By 2027, Capsule alone is expected to reach USD 1166 Mn, with Injection at USD 486 Mn.

Market Dynamics

By 2027, Capsule is the largest of the 2 groups tracked here, at 1.17B USD, 71% of the combined total.

Second place: Injection, 485.94M USD, trailing Capsule by 58%.

Capsule grows to 1.17B USD by 2027, from 850.66M USD in 2018 — 37% up.

Injection: up 61% over the period, 301.07M USD to 485.94M USD.

Injection grows fastest of the group, 61% from 2018 to 2027 — starting smaller doesn't mean staying smaller at this pace.

Add every series together and the total reaches 1.65B USD by 2027, 43% above the 2018 combined figure of 1.15B USD.

Reading This As A Comparison

This chart compares 2 series side by side, not one trend over time. Read them against each other — the biggest number in the room is not automatically the most important line to follow.

Size and growth rate are two different questions here — a series can be small in absolute terms and still be growing the fastest of the group. Check both before drawing a conclusion.

The most practical way to read this is relative: set the Global Isotretinoin Drugs market figures beside other regions or segments of the same market to see where growth is concentrated.

The numbers here come from a market sizing model: historical revenue estimates up to the 2018 base year, then forecasts through 2027 using growth-rate assumptions for each segment. The underlying report explains the methodology in detail.